This shows that, on the one hand, we should keep in mind the possibility of pathogenic mutations in women with DCIS, and on the other hand, in women with already diagnosed BRCA1/2 mutations, we should not ignore the smallest breast lesions, especially if there are calcifications on mammography, a hypoechoic area on ultrasound or non-mass enhancement on breast MRI scans [36,37]. This evidence concerns the gene BRCA1 and ductal breast carcinoma in situ.